Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease

Gut

Volumn 63, Issue 3, 2014, Pages 451-457

  Jharap, Bindia ^a   De Boer, Nanne K H ^a   Stokkers, Pieter ^b,c   Hommes, Daniel W ^d,e   Oldenburg, Bas ^f   Dijkstra, Gerard ^g   Van Der Woude, C Janneke ^h   De Jong, Dirk J ⁱ   Mulder, Chris J J ^a   Van Elburg, Ruurd M ^a   Van Bodegraven, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLISM; IBD CLINICAL; INFLAMMATORY BOWEL DISEASE; PHARMACOKINETICS;

6-MERCAPTOPURINE; ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANEMIA, NEONATAL; AZATHIOPRINE; BIOLOGICAL MARKERS; FEMALE; FETAL BLOOD; FOLLOW-UP STUDIES; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; THIONUCLEOTIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893752804     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303615     Document Type: Article

References (34)

1. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7. (Pubitemid 10125406)
2. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2): CD000545.
3. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (1):CD000478.
4. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7. (Pubitemid 26426470)
5. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-82. (Pubitemid 43833122)
6. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflammatory Bowel Disease 2013;19:15-22.
7. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011;60:198-203.
8. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17. (Pubitemid 36055333)
9. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002;65:240-61. (Pubitemid 34492613)
10. Shim L, Eslick GD, Simring AA, et al. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 2011;5:234-8.
11. Bush MC, Patel S, Lapinski RH, et al. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004;15:237-41. (Pubitemid 38686012)
12. Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 2008;103:1203-9. (Pubitemid 351677969)
13. de Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006;101:1390-2. (Pubitemid 43830009)
14. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53. (Pubitemid 43764536)
15. Shipkova M, Armstrong VW, Wieland E, et al. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003;49:260-8. (Pubitemid 36143448)
16. Dervieux T, Meyer G, Barham R, et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem 2005;51:2074-84. (Pubitemid 41532623)
17. de Graaf P, Vos RM, de Boer NH, et al. Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:1437-42.
18. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90.
19. Pekelharing JM, Souverijn JHM, Hooijkaas H, et al. Handboek medische laboratoriumdiagnostiek. Houten, the Netherlands: Prelum publisher, 2009.
20. Rosenthal P. Assessing liver function and hyperbilirubinemia in the newborn. National Academy of Clinical Biochemistry. Clin Chem 1997;43:228-34. (Pubitemid 27024421)
21. Statistical Package for Social Sciences. Chicago, 2008.
22. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol 2007;3:557-71. (Pubitemid 351324964)
23. Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol 2010;6:689-99.
24. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15. (Pubitemid 34267273)
25. Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973;115:1100-16.
26. Hutson JR, Lubetsky A, Walfisch A, et al. The transfer of 6-mercaptopurine in the dually perfused human placenta. Reprod Toxicol 2011;32:349-53.
27. McLeod HL, Krynetski EY, Wilimas JA, et al. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995;5:281-6.
28. Vettenranta K, Raivio KO. Key enzymes of purine degradation and reutilization in human fetal liver and brain. Biol Neonate 1990;58:311-17.
29. Heilmann L, Rath W, Pollow K. Fetal hemorheology in normal pregnancy and severe preeclampsia. Clin Hemorheol Microcirc 2005;32:183-90. (Pubitemid 40916771)
30. Huang SC, Chang FM. The adverse effect on fetal hemogram by preeclampsia: marked anisocytosis with normocytic, normochromic erythrocythemia as well as thrombocytopenia. Early Hum Dev 1994;37:91-8.
31. Salafia CM, Pezzullo JC, Lopez-Zeno JA, et al. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995;173:1097-105.
32. Bokkerink JP, Stet EH, De Abreu RA, et al. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 1993;45:1455-63. (Pubitemid 23108805)
33. Dervieux T, Blanco JG, Krynetski EY, et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61:5810-16. (Pubitemid 32769099)
34. Foundation Perinatal Registration. Ten years of perinatal registration in the Netherlands. Utrecht: Foundation Perinatal Registration the Netherlands, 2011.